Microarray

Microarray oligonucleotide microarrays [Hu6800 and Hu35KsubA GeneChips (Affymetrix, Santa Clara, CA)] containing a total of 16,063 probe sets representing 14,030 GenBank and 475 The Institute for Genomic Research (TIGR) accession

Materials & Methods

Of 314 tumor samples and 98 normal tissue samples processed, Of 314 tumor samples and 98 normal tissue samples processed, 218218 tumors and tumors and 9090 normal tissue samples passed quality control criteria and normal tissue samples passed quality control criteria and were used for subsequent data analysis.were used for subsequent data analysis.

The resulting dataset contained The resulting dataset contained ~~5 million gene expression values.5 million gene expression values.

Supervised learning method

14 tumor classes:BR, breast adenocarcinoma; PR, prostate adenocarcinoma; LU, lung adenocarcinoma; CR, colorectal adenocarcinoma; LY, lymphoma; BL, bladder transitional cell carcinoma; ML, melanoma; UT, uterine adenocarcinoma; LE, leukemia; RE, renal cell carcinoma; PA, pancreatic adenocarcinoma; OV, ovarian adenocarcinoma; ME, pleural mesothelioma; CNS, central nervous system

hyperplane : best separates samples from two classes

• analysis on primary breast tumors of 117 young patients - 34 : developed distant metastases within 5 years - 44 : disease-free after a period of at least 5 years - 18 : BRCA1 germline mutations - 2 : BRCA2 carriers• the signatures of breast cancer gene expression reported to date allow for patient-tailored therapy strategies

(NKI)

If such results are confirmed by others, doctors may one day be able to discern which patients need the most intensive therapy based in part on how closely their expression profiles match a standard good or poor prognosis profile.

Agendia's first product is MammaPrint(R), a gene expression profiling service to assess the recurrence risk in breast cancer patients. MammaPrint(R) provides valuable assistance for oncologists in formulating tailor-made treatment plans.

檢測費用檢測費用 :US$2196:US$2196

Broadly Altered Gene Expression in Broadly Altered Gene Expression in Blood Leukocytes in Essential Blood Leukocytes in Essential

Hypertension Is Absent During Hypertension Is Absent During TreatmentTreatment

Helena Chon, Carlo A.J.M. Gaillard, Brenda B. van der Meijden, Hilde M. Dijstelbloem, Rob J. Kraaijenhagen, Dik van Leenen, Frank C.P. Holstege, Jaap A. Joles, Hans A.R. Bluyssen, Hein A. Koomans, Branko Braam

From the Department of Nephrology (H.C., J.A.J., H.A.R.B., H.A.K., B.B.), University Medical Center, Utrecht, The Netherlands; Department of Internal Medicine (C.A.J.M.G.) and Department of Clinical Chemistry (B.B.v.d.M., H.M.D., R.J.K.), Meander Medical Center, Amersfoort, The Netherlands; and Genomics Laboratory (D.v.L., F.C.P.H.), University Medical Center, Utrecht, The Netherlands.

(Hypertension. 2004;43:947-951.)

Rapid Communications

Drugs used were angiotensin-converting enzyme (ACE) inhibitors (n=3), -blockers (n=2), or a combination of -blockade and diuretic (n=1).

untreated

treated

• In untreated hypertension patients, 680 genes were differentially regulated (314 up and 366 down).

• In the treated patients, these changes were virtually absent (4 genes up, 3 genes down).

• oxidative stress-related genesoxidative stress-related genes• inflammation-related genesinflammation-related genes• Blood pressure regulation genesBlood pressure regulation genes